NVS BROKERAGE PVT. LTD. 702, Embassy Centre, Nariman Point, Mumbai – 400 021. • Tel.: 61539100 • Fax: 61539134 • E mail:[email protected] 18th Nov 2013 Markets bounce back
Markets snapped a 7-day losing streak as they bounced back smartly on Thursday. Statistics
While the BSE Sensex ultimately closed 205.02pts or 1.02% higher at 20,399.42, the Nifty gained 66.55pts or 1.11% to close at 6,056.15. Broad market indices too ended higher as the BSE Mid Cap and Small Cap indices gained 1.06% and 1.09% respectively. Market breadth was positive as the A/D ratio was 1.33:1 on the BSE. NSE cash turnover was Rs.10,285crs. Vs. Rs.11,517crs. in the previous session. Sectoral and Stock movers
Barring the BSE Healthcare and IT indices, all the sectoral indices ended higher. The top gainers were the BSE Auto, Bankex, Realty and Capital Goods indices. The top gainers from the BSE 30 were Tata Motors, Tata Steel, ICICI Bank and M&M. The top losers were Coal India, Cipla, Sun Pharma and TCS. Way forward
With the markets bouncing back after several sessions of losses, traders will need to watch if the Nifty can cross the immediate resistances of 6079-6102 early next week for the pullback rally to continue. Else, the current downtrend could resume that could take the Nifty towards the 5877 levels. Stock Recommendation:-
Sun Pharmaceutical Industries– Buy (CMP – 601, TARGET – 640)
Drug major Sun Pharmaceutical Industries posted a four-fold increase in consolidated net profit to Rs 1,362.30 crore for the second quarter from a year earlier, when it made a provision for possible damages in a patent case.
The company had posted a profit of Rs 319.64 crore in the same period of the previous financial year. It had set aside Rs 584 crore at the time towards potential damages in respect of patent infringement litigation related to generic versions of Protonix.
Total income rose to Rs 4,311.63 crore from Rs 2,833.13 crore, Sun Pharma said in a statement.
Commenting on the results, Sun Pharma managing director Dilip Shanghvi said, "The performance of all our businesses exceeded our plans. We continue to develop a differentiated and specialty driven product basket. We also continue to review opportunities to expand and strengthen our global footprint."
The Mumbai-headquartered company said the sale of branded prescription formulations in India during the quarter stood at Rs 949 crore, up 17 percent from the same period of previous fiscal.
The company's sales in the US market stood at USD 419 million in the second quarter, up 74 percent from the same period of previous financial year. It accounted for 61 percent of the total sales.
During the quarter, Sun Pharma's subsidiary launched generic Prandin in the US Market. Being the first-to-file, it is entitled to 180-days of marketing exclusivity for this product in the US market, the company said.
The company said its formulation sales in rest of the world (ROW) markets outside of India and the US accounted for USD 79 million in second quarter, registering a growth of 17 percent over the same period of previous financial year.
The drug major also revised its consolidated FY14 revenue growth guidance to 25 percent compared to previous guidance of 18-20 percent.
"The revised guidance takes in to account the performance achieved in H1FY14 as well the risks associated with increase in competition for some products," it added.
Infosys – Buy (CMP – 3362, TARGET – 3445)
Indian IT vendors are in the race for contracts from Obamacare expected to reach USD 50 billion. Even more, the US government has sought proposals for fixing 'healthcare.gov' and players like Infosys and TCS may throw their hat in the ring. CNBC-TV18’s Kritika Saxena reports.
There will be a whole host of contracts coming out and Indian vendors will be biding for data processing, data warehousing and digital contracts. The contacts from the health providers, payers and for the health insurance side, will be coming out approximately by January and contracts from the federal government, state government and academic institutions could be coming out later by February next year.
Cognizant has already bagged a deal in the affordable care, so it could have an edge there.
More importantly, there have been issues with respect to healthcare.gov and several critics have pointed out that this is something that needs to be fixed.
CNBC-TV18 learns from sources that the US government is looking at spending around USD 100 million to fix this. They have already spent around USD 500 million and this is what analysts have also estimated. The US government has floated an request for proposal (RFP) to bring in a consultant to help address this particular issue and the issues that need to be addressed to fix the healthcare.gov and Indian players including TCS, Infosys, Cognizant, Wipro are expected to have got the RFP and will be looking at bidding.
There were no official comments made by any of the companies.
NVS BROKERAGE PRIVATE LIMITED Corporate Office: 702/703, Embassy Centre, Nariman Point, Mumbai- 400 021.EQUITY RESEARCH DESK Ms. Devanshi DhruvaMs. Jinal KothariMr. Omkar GodboleMs. Manisha ThakkarEQUITY DEALING DESK Mr. Nalin Shah - 9322213615 Mr. Rau Thakur - 9820993839 Mr. Raju Mudhupog Mrs. Poonam Sawant Mr. Santosh Kashyap Disclaimer: This document has been prepared by the Research Desk of M/s NVS Brokerage Pvt. Ltd. and is meant for use of the recipient only and is not for circulation. This document is not to be reported or copied or made available to others. It should not be considered to be taken as an offer to sell or a solicitation to support any security. The information contained herein is obtained and collated from sources believed reliable and we do not represent it as accurate or complete and it should not be relied upon as such. The opinion expressed or estimates made are as per the best judgment as applicable at that point of time and are subject to change without any notice. NVS Brokerage Pvt. Ltd. along with its associated companies/ officers/ employees may or may not, have positions in, or support and sell securities referred to herein.
David Bowie is In partnership with Gucci Sound experience by Sennheiser 23 March – 11 August 2013 LAST CHANCE TO SEE DAVID BOWIE IS Around 300,000 people have already seen the V&A’s David Bowie is exhibition as it enters its closing week. The V&A has been running regular late night openings to cope with demand and the exhibition has been open until 22.00 every
Human Factors , 38(4), 574-592, 1996 USERS AS DESIGNERS: HOW PEOPLE COPE WITH POOR HCI DESIGN IN COMPUTER-BASED MEDICAL DEVICES Human Factors , 38(4), 574-592, 1996 Abstract In this paper, we examine how users interact with a computer-based infusion device adapted for terbutaline infusion to treat preterm labor in women experiencing high-risk pregnancies. This study examines: (1) the
NVS BROKERAGE PVT. LTD.